Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Moderna today and set a price target of $95.00. The company’s shares closed last Wednesday at $75.80.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of 42.3% and a 73.9% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Moderna is a Strong Buy with an average price target of $92.15, representing a 18.9% upside. In a report issued on July 22, Jefferies also reiterated a Buy rating on the stock with a $90.00 price target.
Bicycle Therapeutics (BCYC)
Oppenheimer analyst Jay Olson maintained a Buy rating on Bicycle Therapeutics today and set a price target of $27.00. The company’s shares closed last Wednesday at $16.64.
According to TipRanks.com, Olson has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.4% and a 39.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.
Bicycle Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $23.63, a 45.4% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.